Jacroux Richard
Transaction: 03/02/2026
BUY
Change
+13,461
Price
Not reported
Filing
03/04/2026
Type
BUY
ENDRA Life Sciences Inc.
NDRA • Medical - Diagnostics & Research
$4.47
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$11.06M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.22Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 1:12 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$4.47
Change0.00%
Shares Out2.48M
Market Cap$11.06M
Enterprise Value$9.75M
52W Range2.96 - 9.85
Beta-0.07
P/E-1.87
P/B1.75
P/FCF-1.38
EV/EBITDA-1.93
EV/FCF-1.22
Price$4.47
Change0.00%
Shares Out2.48M
Market Cap$11.06M
Enterprise Value$9.75M
52W Range2.96 - 9.85
Beta-0.07
P/E-1.87
P/B1.75
P/FCF-1.38
EV/EBITDA-1.93
EV/FCF-1.22
Earnings Yield-53.47%
FCF Yield-72.39%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.22
Current Ratio1.29
Quick Ratio1.29
Revenue 5Y-100.00%
Volume6.83K
Avg Volume27.29K
EPS Surprise0.14
Investment DNA
How strong this company looks for long-term investors
46
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
67/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
90/100
Why this score▼
Manageable debt level · 0.22Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-10-20
100/100
Bullish
Bullish
4
Hold
0
Bearish
0
Insider Transactions
Recent executive and insider activity
Tokman Alexander Y
Transaction: 03/02/2026
BUY
Change
+26,921
Price
Not reported
Filing
03/04/2026
Type
BUY
Tokman Alexander Y
Transaction: 01/21/2026
BUY
Change
+75,000
Price
Not reported
Filing
01/23/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Jacroux Richard | BUY | +13,461 | Not reported | 03/02/2026 | 03/04/2026 |
| Tokman Alexander Y | BUY | +26,921 | Not reported | 03/02/2026 | 03/04/2026 |
| Tokman Alexander Y | BUY | +75,000 | Not reported | 01/21/2026 | 01/23/2026 |
| Basenese Lou | BUY | +60,324 | Not reported | 01/21/2026 | 01/23/2026 |
| Jacroux Richard | BUY | +20,000 | Not reported | 01/21/2026 | 01/23/2026 |
| Harsh Michael | BUY | +60,324 | Not reported | 01/21/2026 | 01/23/2026 |
| DIGIANDOMENICO ANTHONY | BUY | +60,324 | Not reported | 01/21/2026 | 01/23/2026 |
| DIGIANDOMENICO ANTHONY | BUY | +70,822 | $7.06 | 10/10/2025 | 10/15/2025 |
| DIGIANDOMENICO ANTHONY | BUY | +141,644 | $6.81 | 10/10/2025 | 10/15/2025 |
| DIGIANDOMENICO ANTHONY | BUY | +5,384 | Not reported | 06/11/2025 | 07/01/2025 |
| Harsh Michael | BUY | +5,384 | Not reported | 06/11/2025 | 07/01/2025 |
| Basenese Lou | BUY | +5,384 | Not reported | 06/11/2025 | 07/01/2025 |
| UBS Group AG | BUY | 0 | Not reported | 08/27/2024 | 09/05/2024 |
| UBS Group AG | OPTION | 0 | Not reported | 08/27/2024 | 08/29/2024 |
| Jacroux Richard | OTHER | 0 | Not reported | 08/08/2024 | 08/15/2024 |
| Tokman Alexander Y | BUY | +600 | $1.59 | 01/02/2024 | 02/23/2024 |
| DIGIANDOMENICO ANTHONY | BUY | +600 | $1.59 | 01/02/2024 | 02/23/2024 |
| Harsh Michael | BUY | +600 | $1.59 | 01/02/2024 | 02/23/2024 |
| Basenese Lou | BUY | +600 | $1.59 | 01/02/2024 | 02/23/2024 |
| Thornton Michael Milos | BUY | +15,000 | $1.65 | 05/18/2023 | 05/22/2023 |